Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Time-Restricted eating: a new weapon against fatty liver?

NCT ID NCT07378072

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study tests whether limiting food intake to an 8-hour window each day (without counting calories) can reduce liver fat in people with obesity and a type of fatty liver disease called MASLD. Seventy-two participants will either follow this eating pattern plus standard advice, or receive standard advice alone, for 12 weeks. The main goal is to see if liver fat decreases more with time-restricted eating.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
time-restricted eating (eating only within an 8-hour window each day)
What this could lead to
If it works, this could offer a simple, calorie-free way to reduce liver fat in people with obesity and fatty liver disease.
What could go wrong
This is a small, early-stage trial with only 72 people. The results may not apply to everyone, and sticking to an 8-hour eating window can be hard to maintain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index (BMI) between 30.0 and 49.9 kg/m2 * Age between 18 and 65 years (limits included) * Sedentary (light-intensity physical activity less than 1 hour per week) or moderately active (moderate exercise 1 to 2 hours per week). Self-declared criteria. * Weight stable for at least 3 months prior to the beginning of the study (gain or loss \<4 kg). Self-declared criteria. * Able to give written informed consent * Self-reported eating interval \> 12 hours per day * Subject who owns a smartphone with access to the internet, and agrees to use it in the study * Affiliation with French social security system or beneficiary from such system * Fibroscan® Controlled Attenuation Parameter (CAP) \> 300 dB/ms * Hepatitis B and C serologies negative (or showing past-infection or protective immunization) Exclusion Criteria: * Alcohol intake \> 20 g/day * Night-shift workers or rotating shift workers * Smoking * Patient with diabetes if HbA1c not at target (\<7%) and/or using a non-authorized medication) * Chronic liver disease other than MASLD * Severe hepatic disease (cirrhosis, hepatocellular carcinoma) * Severe cardiac disease (Chronic heart failure classified as being in New York Heart Association (NYHA) Class III or IV) * Severe Kidney disease with CKD-EPI\<30 mL/min/1,73m2 * Initiation of hormonal treatment during the study period * Medications affecting weight or energy balance * Magnetic Resonance Imaging (MRI) not possible due to patient's anthropometric characteristics. Any of the following: * abdominal and/or thoracic circumference with arms greater than 200 cm * Sagittal diameter (or abdominal height, i.e. the distance between the dorsum and the apex of the abdomen, which was measured in the supine position at the midpoint between the iliac crest and the last rib) over 70 cm * body weight over 160 kg * MRI not possible due to the following (an MRI safety screening form will have to be filled for inclusion): presence of a pacemaker or cardiac defibrillator or cardiovascular catheter or neurostimulator or an implantable electronic pump for automated drug injection or an electronically-controlled implantable chamber. Ocular metallic foreign bodies * History of severe eating disorders: Binge Eating Disorder, Bulimia Nervosa; Night eating syndrome * Minors * Adults under guardianship, trusteeship or under safeguard of justice * Other clinical trial participation that could interfere with the study * Pregnant women or women trying to be pregnant * Nursing mothers * Any treatment triggering hepatic steatosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Masld (metabolic dysfunction-associated steatotic liver disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Angers

    NOT_YET_RECRUITING

    Angers, 49993, France

  • CHU Bordeaux

    NOT_YET_RECRUITING

    Bordeaux, 33404, France

  • CHU Dijon-Bourgogne

    NOT_YET_RECRUITING

    Dijon, 21000, France

  • CHU Lyon

    NOT_YET_RECRUITING

    Lyon, 69495, France

  • CHU Marseille

    NOT_YET_RECRUITING

    Marseille, 13000, France

  • CHU Montpellier

    NOT_YET_RECRUITING

    Montpellier, 34000, France

  • CHU Nantes

    RECRUITING

    Nantes, 44093, France

  • CHU Rennes

    NOT_YET_RECRUITING

    Rennes, 35000, France

  • Hôpital Européen Georges Pompidou

    NOT_YET_RECRUITING

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.